Publications by authors named "S F Sakata"
Background: The short-term and midterm impact of gender differences on transcatheter aortic valve implantation (TAVI) has been studied. However, the impact on long-term clinical outcomes remains unclear. The objective of the study was to investigate the impact of gender differences after TAVI on long-term clinical outcomes and structural valve deterioration (SVD).
View Article and Find Full Text PDFA 59-year-old woman presented with multiple mediastinal masses 6 months after post-thymectomy for type B2 thymoma. A diagnosis of small-cell carcinoma (SmCC) via a computed tomography-guided biopsy and fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography revealed no primary lesions outside the anterior mediastinum. The pathologically reevaluated post-thymectomy specimen showed no neuroendocrine differentiation.
View Article and Find Full Text PDFMethane, a greenhouse gas and energy source, is commonly studied using stable isotope signals as proxies for its formation processes. In subsurface environments, methane often exhibits equilibrium isotopic signals, but the equilibration process has never been demonstrated in the laboratory. We cocultured a hydrogenotrophic methanogen with an H-producing bacterium under conditions (55°C, 10 megapascals) simulating a methane-bearing subsurface.
View Article and Find Full Text PDFLong-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Lung Cancer
December 2024
Article Synopsis
- The study investigates long-term outcomes of chemoimmunotherapy for extensive-stage small-cell lung cancer (ES-SCLC) using a large cohort of patients over a minimum follow-up period of 3 years.
- Most participants were trial-eligible, with significantly better overall survival rates compared to those who were not, highlighting the impact of eligibility criteria on treatment effectiveness.
- The results underscore the practical implications of long-term outcomes in real-world settings, aiding clinical decisions for managing ES-SCLC patients.
Osteosarcoma (OS) is a primary malignant bone tumor primarily affecting children and adolescents. The lack of progress in drug development for OS is partly due to unidentified actionable oncogenic drivers common to OS. In this study, we demonstrate that copy number gains of MCL1 frequently occur in OS, leading to vulnerability to therapies based on Mcl-1 inhibitors.
View Article and Find Full Text PDF